Proteomic biomarkers for overall and progression-free survival in ovarian cancer patients

Proteomics - Clinical Applications

Volumn 4, Issue 12, 2010, Pages 940-952

  Høgdall, Estrid ^a   Fung, Eric T ^b   Christensen, Ib Jarle ^c   Yip, Christine ^b   Nedergaard, Lotte ^d   Engelholm, Svend Aage ^d   Risum, Signe ^d   Petri, Anette Lykke ^d   Lundvall, Lene ^d   Lomas, Lee ^e   Høgdall, Claus ^d  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b CIPHERGEN BIOSYSTEMS INC   (United States)

^c FINSEN LABORATORY   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e BIO RAD LABORATORIES   (United States)

Author keywords

Ovarian cancer; Survival

Indexed keywords

APOLIPOPROTEIN A1; BETA 2 MICROGLOBULIN; BETA THROMBOGLOBULIN; BIOLOGICAL MARKER; CYCLOPHOSPHAMIDE; DOXORUBICIN; HEPCIDIN; INTER ALPHA TRYPSIN INHIBITOR; INTER ALPHA TRYPSIN INHIBITOR INTERNAL FRAGMENT; PACLITAXEL; PLATINUM; PREALBUMIN; SERUM AMYLOID A; SERUM AMYLOID A1; TRANSFERRIN; UNCLASSIFIED DRUG;

ADULT; AGE; ARTICLE; BLOOD LEVEL; CANCER CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEOMICS; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY;

ADULT; AGED; AGED, 80 AND OVER; BETA 2-MICROGLOBULIN; BLOOD PROTEINS; CA-125 ANTIGEN; DISEASE-FREE SURVIVAL; FEMALE; GLYCOPROTEINS; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PEPTIDES; PREALBUMIN; PROGNOSIS; PROSPECTIVE STUDIES; PROTEIN ARRAY ANALYSIS; PROTEINASE INHIBITORY PROTEINS, SECRETORY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 78649717071     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.200900171     Document Type: Article

References (33)

1. Nielsen, M. L. S., Høgdall, C. K., The Danish Gynecologic Cancer Database - A nationwide clinical database for ovarian cancer, endometrial cancer and cervical cancer, year 2006-2007. Lægeforeningens Forlag (ISSN 19017877) 2008.
2. Lu, K. H., Patterson, A. P., Wang, L., Marquez, R. T. et al., Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin. Cancer Res. 2004, 10, 3291-3300.
3. Rapkiewicz, A. V., Espina, V., Petricoin, E. F., Liotta, L. A., Biomarkers of ovarian tumours. Eur. J. Cancer 2004, 40, 2604-2612.
4. Soegaard Andersen, E., Knudsen, A., Svarrer, T., Lund, B. et al., The results of treatment of epithelial ovarian cancer after centralisation of primary surgery. Results from North Jutland, Denmark. Gynecol. Oncol. 2005, 99, 552-556.
5. Earle, C. C, Schrag, D., Neville, B. A., Yabroff, K. R. et al., Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J. Natl. Cancer Inst. 2006, 98, 172-180.
6. Engelen, M. J., Kos, H. E., Willemse, P. H., Aalders, J. G. et al., Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma. Cancer 2006, 106, 589-598.
7. Paulsen, T., Kjaerheim, K., Kaern, J., Tretli, S., Trope, C., Improved short-term survival for advanced ovarian, tubal, and peritoneal cancer patients operated at teaching hospitals. Int. J. Gynecol. Cancer 2006, 16, 11-17.
8. van der Burg, M. E., Advanced ovarian cancer. Curr. Treat. Options Oncol. 2001, 2, 109-118.
9. Nielsen, J. S., Jakobsen, E., Hølund, B., Bertelsen, K., Jakobsen, A., Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer. Int. J. Gynecol. Cancer 2004, 14, 1086-1096.
10. Paramasivam, S., Tripcony, L., Crandon, A., Quinn, M. et al., Prognostic importance of preoperative CA-125 in International Federation of Gynecology and Obstetrics stage I epithelial ovarian cancer: an Australian multicenter study. J. Clin. Oncol. 2005, 23, 5938-5942.
11. Tingulstad, S., Skjeldestad, F. E., Halvorsen, T. B., Hagen, B., Survival and prognostic factors in patients with ovarian cancer. Obstet. Gynecol. 2003, 101, 885-891.
12. Britten, R. A., Hardy, C., Vlahou, A., Gregory, B. et al., Identification of reproducible low mass SELDI protein profiles specific to cisplatin resistance in human ovarian cancer cells. Oncol. Rep. 2005, 14, 1323-1330.
13. Petricoin, E. F., Ardekani, A. M., Hitt, B. A., Levine, P. J. et al., Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002, 359, 572-577.
14. Baggerly, K. A., Morris, J. S., Coombes, K. R., Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments. Bioinformatics 2004, 20, 777-785.
15. Zhang, Z., Bast, R. C., Jr., Yu, Y., Li, J. et al., Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res. 2004, 64, 5882-5890.
16. Zhang, Z., Bast, R. C., Jr., Vergote, I., Høgdall, C. et al., A large-scale multi-center independent validation study of a panel of seven biomarkers for the detection of ovarian cancer. J. Clin. Oncol. 2006, 24, 5057.
17. Tingulstad, S., Hagen, B., Skjeldestad, F. E., Onsrud, M. et al., Evaluation of a risk of malignancy index based on serum CA125, ultrasound findings and menopausal status in the pre-operative diagnosis of pelvic masses. Br. J. Obstet. Gynaecol. 1996, 103, 826-831.
18. Jacobs, I., Oram, D., Fairbanks, J., Turner, J. et al., A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br. J. Obstet. Gynaecol. 1990, 97, 922-929.
19. Andersen, E. S., Knudsen, A., Rix, P., Johansen, B., Risk of malignancy index in the preoperative evaluation of patients with adnexal masses. Gynecol. Oncol. 2003, 90, 109-112.
20. Petri, A. L., Anja Hviid Simonsen, A. H., Estrid Høgdall, E., Christensen, I. J. et al., Comparison of proteomic biomarker panels in urine and serum for ovarian cancer diagnosis. Proteomics Clin. Appl. 2010, 4, 304-314.
21. Kemna, E. H., Tjalsma, H., Podust, V. N., Swinkels, D. W., Mass spectrometry-based hepcidin measurements in serum and urine: analytical aspects and clinical implications. Clin. Chem. 2007, 53, 620-628.
22. Carrette, O., Demalte, I., Scherl, A., Yalkinoglu, O. et al., A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease. Proteomics 2003, 3, 1486-1494.
23. Kozak, K. R., Su, F., Whitelegge, J. P., Faull, K. et al. Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics 2005, 5, 4589-4596.
24. Shi, L., Zhang, J., Wu, P., Feng, K. et al., Discovery and identification of potential biomarkers of pediatric acute lymphoblastic leukemia. Proteome Sci. 2009, 7, 7.
25. Cox, D. R., Regression models and life tables. J. R. Stat. Soc. B 1972, 34, 187-220.
26. Harrel, F. E. J., Lee, K. I., Mark, D. B., Multivariate prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat. Med. 1996, 15, 361-387.
27. Rai, A. J., Zhang, Z., Rosenzweig, J., Shih, I. et al., Proteomic approaches to tumor marker discovery. Arch. Pathol. Lab Med. 2002, 126, 1518-1526.
28. Kozak, K. R., Amneus, M. W., Pusey, S. M., Su, F. et al., Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: potential use in diagnosis and prognosis. Proc. Natl. Acad. Sci. USA 2003, 100, 12343-12348.
29. Zhao, Q., Duan, W., Wu, Y. M., Qian, X. H., Deng, X. H., [Analysis of serum biomarkers of ovarian epithelial cancers based on 2-DE DIGE and MALDI TOF/TOF]. Zhonghua Zhong Liu Za Zhi 2008, 30, 754-758.
30. Mohamed, E., Abdul-Rahman, P. S., Doustjalali, S. R., Chen, Y. et al., Lectin-based electrophoretic analysis of the expression of the 35 kDa inter-alpha-trypsin inhibitor heavy chain H4 fragment in sera of patients with five different malignancies. Electrophoresis 2008, 29, 2645-2650.
31. Hann, H. W., Lange, B., Stahlhut, M. W., McGlynn, K. A., Prognostic importance of serum transferrin and ferritin in childhood Hodgkins disease. Cancer 1990, 15, 313-316.
32. Blum, C., Graham, A., Yousefzadeh, M., Shrout, J. et al., The expression ratio of Map7/B2M is prognostic for survival in patients with stage II colon cancer. Int. J. Oncol. 2008, 33, 579-584.
33. Hernadi, Z., Molnar, V., Juhasz, B., Polka, R., Margitai, B., Der pradiktive Wert der Tumormarkerkombination CA-125 und Beta-2-Mikroglobulin bei Ovarialkarzinom. Zentralbl. Gynakol. 1992, 114, 6-9.